|
[1] Shepherd J, Jones J, Hartwell D, et al. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation.Health Technol Assess, 2007,11(11), 1-205.
[2] Manns M P, Wedemeyer H, Cornberg M. Treating viral hepatitis C: eficacy,side effects,and complications.Gut,2006,55(9):1350-1359.
[3] Manns M P, Foster G R, Rockstroh J K. et al. The way forward in HCV treatment-finding the fight path.Nat Rev Drug Discov,2007,6(12):991-1000.
[4] Soler M,McHutchison J G,Kwoh T J,et al.Virological effects of ISIS 14803, an antisense oligonucleotide inhibitor of hepatitis C virus (HCV) internal ribosome entry site (IRES),on HCV IRES in chronic hepatitis C patients and examination of the potential role of primary and secondary HCV resistance in the outcome of treatment.Antivir Ther,2004,9(6):953-968.
[5] De Francesco R,Carfi A.Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus.Adv Drug Deliv Rev,2007,59f121:1242-1262.
[6] McHutchison J,Everson G,Gordon S,et al. PROVE.1:results from a phase 2 study of telaprevir with peginterferon alfa--2a and ribavirin in treatment·-naive subjects with hepatitis.J Hepatoll,2008,48 Suppl 2:4.
[7] McHutchison J G, Shiffman M L, Terrault N, et al.A phase 2b study of telaprevir with peginterferon--alfa--2a and ribavirin in hepatitis C genotypc 1 null and partial responders and relapsers following a prior course of peginterferon··alfa--2a/b and ribavirin therapy: PROVE3 Interim Results.AASLD.CA:San Francisco,2008.
[8] Kwo P,Lawitz E,McCone J,et al.Interim results from HCV SPRINT·-h RVR／EVR from phase 2 study of boceprevir plus Pegintron (peginterferon alfa-2b)/ribavirin in treatment naive subjects with HCV genotype l CHClJ1.J Hepatol,2008,48 Suppl 2:372.
[9] Leveque V,Le Pogam S,Kang H,et al.Antiviral potency of R1479,active compound derived in viyo from prodrug R1626, demonstrated across HCV genotypes 1-6 in NS5B recombinant enzymes and HCV replicons. J Hepatol,2008,48 Suppl 2:3 1 9.
[10] Pockros P J,Nelson D,Godofsky E,et al.R1626 plus peginterferon alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin.Hepatology,2008,48(2):385-397.
[11] Pockros P,O Brien C,Godo~ky E,et al.Valopicitabine (NM283),alone or with peg-interferon,compared to peg interferon／ribavirin(pegIFN／RBV)retreatment in hepatitis C patients with prior non-response to pegIFN／RBV:week 24 results .Jurnal of Hepatology, 2007, 46:55.
[12] Chandra P,Raible D,Moyer L,et al.Safety and pharmacokinetics of the non-nucloside polymerase inhibitor,HCV-796:results of a randomized,double blind placebo controlled,ascending single dose study in healthy subjects lJI.Hepatol,2006,44 Suppl 2:208.
[13] Knetenmn N M,Howe A Y,Gao T,et al.HCV796:A selective nonstructural protein 5B polymerase inhibitor with potent antihepatitis C virus activity in vitro,in mice with chimeric human livers, and in humans infected with hepatitis C virus.Hepatology,2009,49(3):745-752.
[14] Crabb4 R,Vuagniaux G,Dumont J M,et al.An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C 『J1.Expert Opin Investig Drugs,2009,18(2):211-220.
[15] Mathy J E,Ma S,Compton T,et al.Combinations of cyclophilin inhibitor NIMS l 1 with hepatitis C virus NS3/4A protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance.Antimicrob Agents Chemother,2008,52(9):3267-3275.
[16] Alt M,Renz R,Hofschneider P H,et al.Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides.Hepatology,1995,22(3):707-717.
[17] King R W,Zecher M,Jeffries M W,et al. A cell basedmodel of HCV negative strand RNA replication utilizing a chimefic hepatitis C virus／reporter RNA template.Antivir Chem Chemother, 2002,13(6):353-362.
[18] 刘水平,谭德明,杨永峰,等.丙型肝炎病毒5'端非编码区和NS3蛋白酶共调控外分泌性碱性磷酸酶表达细胞模型的建立及意义.中华肝脏病杂志,2004,12(9):552-554. Liu S P, Tan D M, Yang Y F, et al. Chinese Journal of Hepatology, 2004,12(9):552-554.
[19] 池晓霞,谢妮,孙彦.一种新型抗HCV药物筛选细胞模型建立的研究.深圳中西医结合杂志,2005,15(4):216-219. Chi X X, Xie N, Sun Y. Shenzhen Journal of Integrated Traditional Chinese and Western Medicine, 2005,15(4):216-219.
[20] Lohmann V,Korner F,Koch J,et al.Replication of subgenomic hepatitis C virus RNAs in ahepatoma cell line.sciencc,1999,285:110-113.
[21] Koyama T,Sakamoto N,Tanabe Y,et al.Divergent ac· tivities of interferon Mpha subtypes against intracellular hepatitis C vires replication.Hepatology Research,2005,34(1):41-49.
[22] Blight K J, Mckeating J A, Marcotrigiano J, et al. Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J Virol, 2003, (77): 3181-3190.
[23] Heller T,Saito S,Auerbach J,et al.An in vitro model of hepatitis C virion production.Proc Nail Acad Sei USA,2005,102(7):2579-2583.
[24] 姚相杰,郭佳,郑从义,等.丙肝病毒全基因组eDNA克隆侵染细胞培养体系的建立.科学通报,2004,49(10):965-970. Yao X J, Guo J, Zheng C G,et al. Chinese Science Bulletin, 2004,49(10):965-970.
[25] Zhong J,Gastaminza P,Cheng G,et al.Robust hepatitis C virus infection in vitro.Proe Nail Acad Sei USA,2005,102 (26):9294-92919.
[26] Lindenbach B D,Evans M J,Syder A J,et al.Complete replication of hepatitisc virus in cell culture.Science,2005,309(5734):623-626.
[27] Cai Z,Zhang C,Chang K S,et al.Robust production of in fecfions hepatitis C virus(HCV)from stably HCV cDNA-trails fected human hepatoma cells.J Virol,2005,79(22):13963-13973.
[28] Mc Hutchison J G, Patel K, Pockros P, et al. Aphase 1 trial of all antisense inhibitor of hepatitis C virus(ISIS 14803), administered to chronic hepatitis C patients. J Hepatol, 2006,44: 88-96.
[29] Arvind S, Samuel K. Plant-derived compounds in clinical trials. Drug Discovery Today, 2008, 13: 56-64.
[30] Claire G, Lydiane G, Patrick M, et al. Cellular models for the screening and development of anti-hepatitis C virus agents. Pharmacology & Therapeutics, 2009, 124:1-22.
[31] Kim C S, Jung J H, Wakita T, et al. 2007. Monitoring the antiviral effect of alpha interferon on individual cells. J. Virol, 2007, 81 (16): 8814-8820.
[32] Schaller T, Appel N, Koutsoudakis G, et al. Analysis of hepatitis C virus superinfection exclusion by using novel fluorochrome gene-tagged viral genomes. J Virol, 2007, 81 (9): 4591-4603.
[33] Zhang Y, Weady P, Duggal R, et al,. Novel chimeric genotype 1b/2a hepatitis C virus suitable for high-throughput screening. Antimicrob. Agents Chemother,2008, 52 (2): 666-674.
[34] Wu Y, Liao Q J, Yang R G,et al. A novel luciferase and GFP dual reporter virus for rapid and convenient evaluation of hepatitis C virus replication. Virus Research, 2011, 155: 406-414.
|
